Evidence map›Paper›PMID 30145825›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2018

Increased substantia nigra echogenicity in LRRK2 family members without mutations.

Mariel Pullman, Roberto Ortega, Amanda Glickman, Andres Deik, Deborah Raymond, Karen Marder, Nir Giladi, Susan Bressman, Johann Hagenah, Norbert Brüggemann and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Multiple sclerosis inFrontiers in neurology · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mariel PullmanIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Roberto OrtegaMount Sinai Beth Israel, Neurology, New York, New York, USA.
Amanda GlickmanMount Sinai Beth Israel, Neurology, New York, New York, USA.
Andres DeikIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Deborah RaymondMount Sinai Beth Israel, Neurology, New York, New York, USA.
Karen MarderColumbia University, Neurology, New York, New York, USA.
Nir GiladiTel-Aviv Souraskos Medical Center, Neurology, Tel-Aviv, Israel.
Susan BressmanIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Johann HagenahWestküstenklinikum Heide, Neurology, Heide, Germany.
Norbert BrüggemannUniversity of Lübeck, Neurology, Lübeck, Germany.ORCID 0000-0001-5969-6899
Rachel Saunders-PullmanIcahn School of Medicine at Mount Sinai, New York, New York, USA.

Funding

Evaluation of glucocerebrosidase pathway biomarkers in Parkinson DiseaseU01NS094148 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAINC, DIMITRI, SAUNDERS-PULLMAN, RACHEL · 2015 to 2017
$1.4M
Phenotypic Spectrum of LRRK2 MutationsK02NS073836 · NINDS · BETH ISRAEL MEDICAL CTR (NEW YORK) · PI SAUNDERS-PULLMAN, RACHEL · 2011 to 2015
$879k
Bigglesworth Family FoundationMichael J. Fox FoundationNIH-NINDS K02-NS073836NIH-NINDS NIH-NINDS U01-094148NINDS NIH HHS K02 NS073836NINDS NIH HHS U01 NS094148
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Family HealthAdultAgedFemaleHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleMiddle AgedMutationParkinson DiseaseSubstantia NigraUltrasonography, Doppler, TranscranialLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, human

Identifiers

PMID30145825
PMCPMC6346431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.